Rodríguez-Hernández H, Jacobo-Karam JS, Guerrero-Romero F

Language: Spanish
References: 40
Page: 303-310
PDF size: 140.31 Kb.

ABSTRACT

Prevalence of peptic ulcer (PU) and risk factors associated with its recurrence are unknown among the Mexican population. Objective: To determine clinical features and risk factors associated with peptic ulcer recurrence. Material and Methods: Five-year follow-up study that included 211 men and 140 women 20 years age or older. PU diagnosis was made by clinical and endoscopic criteria. Associated risk factors such as NSAIDs use, smoking, alcohol consumption, and H. pylori infection were assessed. Clinical recurrence was defined as the time between basal diagnosis and the first PU clinical drop. Results: Diagnosis of duodenal ulcer (DU) and gastric ulcer (GU) was documented in 41.9 and 58.1% of subjects. Predominant risk factor for DU was smoking, and NSAID intake for GU. H. pylori were documented in 39.3%. Sixty-five years of age or older (61 and 33% for GU and DU, respectively), and three or more associated risk factors (70%) were the main associated causes for PU recurrence. PU recurrence associated with Hp was 34%. Conclusions: GU frequency was the highest and associated risk factors for its recurrence were NSAID intake, 65 years of age or older, and Hp infection.

REFERENCES

1. Kurata JH. Ulcer epidemiology: an overview and proposed research framework. Gastroenterology 1989;96:569-80.

2. Villalobos-Pérez JJ, Quiñones N, Cruz G, Vargas F. Epidemiología de la ulcera péptica en el Instituto Nacional de la Nutrición "Salvador Zubirán". Rev Gastroenterol Mex 1990;55:55-60.

3. Bobadilla J, Villalobos JJ, Gómez A, Vargas F. Epidemiología de la úlcera péptica. Rev Gastroenterol Mex 1993;58:299-300.

4. Rodríguez-Hernández H, Guerrero-Romero J, Jacobo-Karam J, Rodríguez-Morán M. Factores de riesgo clínico para hemorragia y recurrencia de úlcera péptica. Rev Gastroenterol Mex 1995;60(Suppl 3):38.

5. García-Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal antiinflammatory drugs. Lancet 1994;343:769-72.

6. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998;93:1409-15.

7. Friedman LS, Martin P. The problem of gastrointestinal bleeding. Gastroenterol Clin North Am 1993;22(4):717-21.

8. Northfield TC. Factors predisposing to recurrent hemorrhage after acute gastrointestinal bleeding. Br Med J 1971;1:26-8.

9. Jones PF, Johnston SJ, McEwan AB, Kyle J, Needham CHD. Further hemorrhage after admission to hospital for gastrointestinal bleeding. Br Med J 1973;3:660-4.

10. Peterson WL. Clinical risk factors. Gastrointest Endosc 1990;36(Suppl):14-15.

11. Henry D, Dobson A, Turner C. Variability in the risk of mayor gastrointestinal complications from nonaspirin nonsteroidal antiinflammatory drugs. Gastroenterology 1993;105:1078-88.

12. Van Deventer GM, Elashoff JD, Reedy TJ, Schneidman D, Walsh JH. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl J Med 1989;320:1113-19.

13. Jensen D, Cheng S, Kovacs T, Randall G, Jensen ME, Reedy T, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994;330:382-6.

14. Johnson HD. Classification of blood group characteristic secretion pattern. Ann Surg 1965;162:996-9.

15. O'Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med 1998;338:592-601.

16. Villalobos JJ, Menéndez VM, Tanimoto M, Guerrero A. Ulcera péptica en el Hospital de Enfermedades de la Nutrición. Rev Invest Clin 1960;12:432-6.

17. Martín V, Villalobos JJ. Ulcera péptica en el anciano. Rev Gastroenterol Mex 1988;53:332.

18. Kurata JH, Corboy ED. Current peptic ulcer time trends. An epidemiologic profile. J Clin Gastroenterol 1988; 10:259-68.

19. Stemmermann GN, Marcus EB, Buist AS, Maclean CJ. Relative impact of smoking and reduced pulmonary function on peptic ulcer risk. Gastroenterology 1989;96:1419-24.

20. Sugawa C, Steffes CP, Nakarnura R, Sferra J, Sferra C, Sugimura Y, Fromm D. Upper GI bleeding in an urban hospital. Ann Surg 1990;212:521-27.

21. Gabriel SE, Jakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.

22. Soll AH. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med 1990;322:909-16.

23. Wolfe M, Lichtnftein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.

24. Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S. Major upper gastrointestinal tract bleeding: relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med 1988;148:281-5.

25. Cryer B, Feldman M. Effects of nonsteroidal antiinflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal antiinflammatory drug-induced damage. Arch Intern Med 1992;152:1145-55.

26. Korman MG, Hansky J, Eaves ER, Schmidt GT. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983;85:871-7.

27. Sontag S, Graham DY, Belsito A, Weiss J, Farley A, Grunt R, et al. Cimetidine, cigarette smoking, and recurrence of duodenal ulcer. N Engl J Med 1984;311:689-93.

28. Sontag SJ. Current status of maintenance therapy in peptic ulcer disease. Am J Gastroenterol 1988;83:607-12.

29. Armstrong D, Arnold R, Classen M, Fisher M, Goebell H, Schepp W, Blum AL. RUDER - a prospective, two-year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. Dig Dis Sci 1994;39:1425-33.

30. Battaglia G, Farini R, Di Mario F, Picuoli A, Plebani M, Vianello F, et al. Recurrence of duodenal ulcer under continuous antisecretory treatment- an approach to the detection of predictive markers. Am J Gastroenterol 1984;79:831-6.

31. Bardhan KD. Intermittent treatment of duodenal ulcer for long term medical management. Postgrad Med J 1988;64 (Suppl 1):40:6.

32. Strum WB. Prevention of duodenal ulcer recurrence. Ann Intern Med 1986;105:757-61.

33. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reviews duodenal and gastric ulcers recurrence: A review. Gastroenterology 1996;110:1244-52.

34. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994;331:717-27.

35. Graham TY, Colon-Paga J, Morse RS, Johnson TL, Walsh TH, McCullough AJ, Marks JW, et al. Ulcer recurrence following duodenal ulcer healing with omeprazol. Ranitidine, or placebo: a double-blind, multicenter, 6-month study. Gastroenterolgy 1992;102:1289-94.

36. Gilbert JP, Blanco M, Mateos JM, Fernández-Salazar L, Fernández-Bermejo M, Cantero J, Pajares JM. H. pylori -negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999;44:2295-2302.

37. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal antiinflammatory drugs: a case-control study. Gastroenterology 1999;116: 1305-09.

38. Chan FKL, Sung JJY, Chung S, To KF, Yung MY, Leung VKS, Lee YT, et al. Randomised trial of eradication of Helicobacter pylori before nonsteroidal antiinflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350: 975-79.

39. Taha AS, Dahill S, Morran CH, Hudson N, Hawkley CJ, Lee FD, Sturrock RD, Russell RI. Neutrophils, Helicobacter pylori , and nonsteroidal antiinflammatory drug ulcers. Gastroenterology 1999;116:254-58.

40. Rodríguez-Hernández H, Sánchez-Anguiano LF, Quiñónez E. Erradicación de Helicobacter pylori en úlcera péptica y gastritis crónica. Ensayo clínico aleatorio. Rev Gastroenterol Mex 1998;63:21-7.